Mifeprex Labeling Change: “Routine” Response To Adverse Events, FDA Says
Executive Summary
FDA's decision to strengthen warnings on Danco's Mifeprex (mifepristone) is not a signal that the agency will move to pull the product off the market, Center for Drug Evaluation & Research Acting Director Steven Galson, MD, said Nov. 16
You may also be interested in...
Danco Mifeprex adverse events
Revised 1labeling for Danco's abortifacient Mifeprex (mifepristone/RU-486) expands list of potential adverse reactions to include allergic reaction, hypotension, light-headedness, loss of consciousness, post-abortal infection, ruptured ectopic pregnancy, shortness of breath and tachycardia. Reports of infections, ruptured ectopic pregnancies and bleeding prompted FDA to strengthen Mifeprex' "black box" warning in November (2"The Pink Sheet" Nov. 22, 2004, p. 8)...
Danco Mifeprex adverse events
Revised 1labeling for Danco's abortifacient Mifeprex (mifepristone/RU-486) expands list of potential adverse reactions to include allergic reaction, hypotension, light-headedness, loss of consciousness, post-abortal infection, ruptured ectopic pregnancy, shortness of breath and tachycardia. Reports of infections, ruptured ectopic pregnancies and bleeding prompted FDA to strengthen Mifeprex' "black box" warning in November (2"The Pink Sheet" Nov. 22, 2004, p. 8)...
Pfizer Depo-Provera “Black Box” Urges Short-Term Use Only Due To Bone Loss
A "black box" warning added to Pfizer's contraceptive injection Depo-Provera (medroxyprogesterone) states the drug should be treated as second-line for long-term use due to the potential for bone loss